FDA approves Jemperli plus chemo in endometrial cancer
Drug Discovery World
AUGUST 4, 2023
GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). As a clinician, I celebrate the practice-changing potential of adding Jemperli to chemotherapy for patients.”
Let's personalize your content